The TGFBI cDNA was amplified by PCR from the cDNA clone MGC:3646 (IMAGE:2958878) using TGFBI specific primers forward 5 -CCCAAGCTTGCCGCCACCATGGCGCTCTTCGTGCGG-3 and reverse 5 -CCC-AAGCTTATGCTTCATCCTCTCTAATAACTTTTG-3 and cloned into the HindIII site of the PCS2+mt plasmid (Invitrogen) in frame with the myc coding sequence (pCSMT-TGFBI). To generate the his-myc tagged rTGFBI (AAA07) construct TGFBI cDNA was amplified using TGFBI specific primers forward 5 -CCG-CTCGAGGCCGCCACCATGGCGCTCTTCGTGC-3 and reverse 5 -CCCCCGCGGATGCTTCATCCTCTCTAA-TAAC-3 and cloned into the XhoI and SacII sites of pcDNA4/myc-his B (Invitrogen).
Real-time PCR
Total RNA was isolated from primary tumours and cancer cell lines using Trizol reagent (Gibco BRL) and 1 µg was reverse transcribed with the Reverse Transcription Kit (Applied Biosystems). PCR was carried out using SYBR Green PCR Master Mix (Applied Biosystems) and an ABI 7900 Sequence Detection System (Applied Biosystems). TGFBI was amplified using forward 5 -AGCCCTGCCACCAAGAGAA-3 and reverse 5 -CTCCGCTAACCAGGATTTCATC-3 primers. The specificity of the PCR products was confirmed by melting curve analysis and amplification was normalized against GAPD amplified using forward 5 -GCAAATTCCATGGCACCGT-3 and reverse 5 -TCGCCCCACTTGATTTTGG-3 primers. Expression ratios relative to SKOV-3TR expression were calculated as previously described (Pfaffl, 2001 ) and log 2 transformed for statistical comparison.
Immunoblot analysis Antibodies
Anti-TGFBI antibodies were either obtained from Santa Cruz (for immuno-blotting of cultured media and immuno-cytochemistry) or were a kind gift from Dr Ching Yuan (for blots of protein lysates and immunohistochemistry). Other antibodies used were against cleaved caspase 3 (Chemicon), alpha tubulin (Sigma), gamma tubulin (Sigma), cyclin B1 (Vision Biosystems), BubR1 (Abcam), detyrosinated tubulin (Glu-tubulin, [Chemicon] ), myc (Cancer Research UK), gm130 (BD Transduction), alphaVbeta3 (Chemicon), FAK (Abcam) and FAK-P397 (Abcam). Secondary anti rabbit and anti-mouse antibodies were either horseradish peroxidase-tagged (DakCytomation) or fluorescine, texas red or Cy5 tagged (Amersham Biosciences)
Conditioned medium
Cells were grown in T75 flasks until confluence and conditioned medium was cleared by centrifugation at 10, 000 × g for 30 min and either used directly for immunoblotting or fractionated as previously described (Billings et al., 2002) . In brief, cleared medium was put onto strong cation exchange columns (Amersham Biosciences), the column was washed with 10 ml of 50 mM phosphate, pH 6.5, 50 mM NaCl, and bound proteins were eluted with a linear NaCl gradient (0.05-1 M) in the same buffer. Aliquots from each fraction were analyzed by immunoblotting. TGFBI was maximally eluted in fractions 9-12 (out of 20 fractions); these were subsequently used in comparison between different cell types.
Western blot analysis
Aliquots of cell lysates containing equal protein mass or culture medium were resolved on SDS-polyacrylamide gel electrophoresis, transferred to Immobilon-P membranes (Millipore) and probed with primary antibody at the recommended dilutions followed by the relevant secondary antibodies conjugated with horseradish peroxidase in a 1:10,000 dilution. After washing, proteins were detected by chemiluminescence (ECL, Amersham).
Estimation of Glu-tubulin formation
Cells were plated at a density of 1 × 10 5 per well in 24-well plates, serum starved for 24 hr and treated with the indicated concentrations of paclitaxel for 1 hr. Protein lysates were collected in 150 µl of protein lysis buffer at room tempeature. 20 µl of lysates were denatured using 5× Laemmli buffer and boiling at 110
• C for 3 minutes before being resolved on SDS-polyacrylamide gel electrophoresis. Transfer was performed to Immobilon-FL membranes (Millipore) follwed by blocking using 5% milk for 1 hr and probing using rabbit anti-Glu-tubulin antibody and mouse anti-alpha tubulin antibody overnight. Fluoresceintagged anti-rabbit and Cy5-tagged anti-mouse secondary antibodies were applied for 4 hr for detection. Membranes were scanned using the Typhoon Trio Scanner (GE Healthcare) to measure the fluorescence intensity volumes for individual bands at appropriate wavelengths using the ImageQuant V2005 software (GE Healthcare) and the ratio of fluorescein over Cy5 values were estimated. Glu-tubulin formation was expressed as fold increase over the baseline of no paclitaxel treatment.
Estimation of soluble tubulin fraction
Cells were lysed in a microtubule stabilizing buffer containing 20 mmol/l Tris-HCL (pH 6.8), 0.14 mol/l NaCl, 0.5% NP40, 1 mmol/l MgCl2, 2 mmol/l EGTA and 4 µg/ml paclitaxel as previously described (Minotti et al., 1991) . The insoluble tubulin fraction was separated using centrifugation at maximum speed for 10 minutes at 4
• C and the resulting pellet was resuspended using 1× Laemmli buffer. Equal volumes of the soluble and insoluble fractions were loaded for western blotting as described above using Immobilon-FL membranes (Millipore). Membranes were probed using anti-alpha tubulin antibody which was detected using Cy5-tagged anti-mouse secondary antibodies. Intensity volumes were quantified as above.
Estimation of paclitaxel uptake
Cells were plated into Lab-Tek 8-well chamber slides and cultured overnight. Cells were washed with PBS twice before the addition of 100 µL of TubulinTracker Green (Invitrogen, Oregon Green 488-taxol) at the recommended dilution in PBS with addition of Hoechst 33342 (Sigma) and with or without verapamil at 3 µM. After 30 minutes the fluorescent taxol mix was washed off with PBS and images immediately collected on an Olympus ScanR system (Olympus Soft Imaging Solutions, OSIS) using a 20x lens. 25 images were collected per sample. Images were subsequently processed using the ScanR Analysis software (OSIS) and the cytoplasmic concentration of retained fluorescent taxol was estimated in a ring around each nucleus.
Time-lapse imaging
1 × 10 5 cells were plated on cover glass chambers (Lab-tech). Images were obtained using 40× lens on a Nikon Eclipse TE 2000-E microsope (Nikon) in an incubator at 37
• C and humidified 5% CO 2 . Images were collected every minute for 16 hr using the NIS-Elements AR V 2.3 imaging software (Laboratory Imaging). The time from the start of prometaphase, as evidenced by nuclear membrane breakdown and chromatin condensation, to the start of telophase, as evidenced by the start of the constriction ring formation, was scored for individual cells.
Cell cycle progression
Hela cells were seeded into 24-well plates at a density of 1 × 10 5 cells per well. Cells were transfected using either TGFBI siRNA or non-targeting siRNA controls. Knock-down of TGFBI was confirmed by western blotting 48 hr following transfection. 24 hr following transfection double thymidine block and release (first block for 19 hr, release for 9 hr and second block for 16 hr) was performed using 2.5 µM of thymidine (Sigma). Cells were harvested after synchronization and every 3 hr for 24 hr, stained using propidium iodide (sigma) staining and analyzed using flow cytometry.
Synthesis of rTGFBI
The human embryonic kidney 293T-EBNA cells (Invitrogen) were cultured in DMEM supplemented with 10% (v/v) bovine calf serum, 100 IU/ml penicillin and 100 µg/ml streptomycin and transfected with the AAA07 construct (2.5 µg/cm rTGFBI coating and cell adhesion
Tissue culture plastic surface coating was performed as previously described (Billings et al., 2002) . For adhesion assays, medium-binding polystyrene 96-well plates (Corning) were coated with rTGFBI , fibronectin (Chemicon) or polylysine at 20 µg/ml in PBS or PBS alone overnight at 4
• C. Plates were washed with PBS and blocked using 2% milk at 37
• C for 1 hr. Cells were trypsinized and counted, and trypsin was neutralized using full media. Cells were plated into wells (5 × 10 4 cells/well) and incubated for 1 hr at 37
• C and then washed twice using PBS. To quantify cell adhesion, cells were stained using the CyQuant cell proliferation assay kit (Invitrogen) according to the manufacturer's instructions. To test the effect of integrin blocking on adhesion, suspension cells were incubated with the mouse monoclonal blocking antibody anti-alphaVbeta3 (Chemicon) for up to 1 hr (1 in 100 dilution) at 37
• C before seeding.
For testing the effect of rTGFBI on Glu-tubulin formation using immuno-fluorescence or on Glu-tubulin formation and FAK phosphorylation using western blotting, Lab-Tek II glass chambers (Nalge Nunc International) or 6-well plates (Corning), respectively, were used for coating as above. For testing the effect of rTGFBI on paclitaxel-induced caspase activation, white flat-bottom 384-well plates (Corning) were used for coating.
Immunohistochemistry
Paraffin-embedded blocks were sectioned at 5 µm thickness. Antigen retrieval was achieved by microwave boiling in a preheated citric acid buffer solution. Primary antibody against TGFBI was a kind gift of Dr Ching Yuan and was used at 1 in 500 dilution. Antibody detection was performed using streptavidinbiotin labeling. Visualization was achieved using two methods; di-amino benzidine chromagen method (Dako) or the EnVision method (Dako) following the manufactures instructions. All slides were reviewed blinded to outcome data. All slides were stained in duplicates on two separate occasions and were scored separately to assess reproducibility.
Immunofluorescence, image collection and processing Sub-confluent cells growing on cover slips or 20 µm thick frozen-sectioned tissue samples on uncoated slides were fixed immediately using 4% paraformaldehyde in PBS for three to five minutes. Processing, blocking and washing were performed as described previously (Mills et al., 2000) . Primary antibodies were incubated at recommended dilutions for 2 hr at 37 • C. Primary antibodies were detected using FITC or Texas Red conjugated anti-mouse or anti-rabbit secondary antibodies (Amersham Biosciences) as appropriate for 1 hr at 37 • C. DNA in nuclei was stained using Hoechst 33258 (Sigma). Images were collected using a BioRad Radiance Lasersharp 2000 software on a Nikon TE2000-U with a 60× planapo NA 1.4 lens. Three-dimensional reconstruction of Z-stack images was performed using Volocity 3.0 software (Improvision).
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Recruitment
Study recruitment was from January 2002 to December 2004. Patients with histologically confirmed advanced (Stages III and IV) epithelial ovarian cancer with a WHO performance status of 0 or 1 were eligible to participate. Exclusion criteria were (1) Non-epithelial ovarian tumours (2) Patients who had received prior chemotherapy or radiotherapy (3) Patients who were not fit to receive paclitaxel treatment. The study was approved by the Cambridge Local Research Ethics Committee (LREC). All patients gave written informed consent prior to participation.
Procedures
All patients with suspected ovarian cancer (Raised CA 125 and a complex pelvic mass in a perimenopausal woman) were radiologically staged using CT scan and a chest x-ray. Patients with evidence of intraabdominal metastasis and/or malignant pleural effusion were approached for entry to the study. Tissue biopsy was obtained either under radiological control (core needle biopsy) or via laparoscopic surgery (punch biopsy). Patients with histologically confirmed epithelial ovarian cancer were randomized to receive either three cycles of carboplatin (AUC 7) or paclitaxel (175 mg/m 2 ). Patients with stable or responding disease had interval debulking surgery. Following surgery, patients received three cycles of combination chemotherapy (carboplatin and paclitaxel) followed by a further three cycles of the drug that they did not initiate treatment on ( Figure S6A ).
Response evaluation
For the purpose of comparing TGFBI expression between paclitaxel-resistant and paclitaxel sensitive patients, CA 125 response to the initial three cycles of single agent treatment was evaluated. CA 125 (marker) response was defined as previously described (Rustin et al., 1996; Bridgewater et al., 1999) . In brief, paclitaxel-sensitive patients were defined as those who show either (1) a 50% decrease in serum CA 125 level and the sample showing the 50% decrease was confirmed by a susequent sample or (2) a 75% decrease in any sample compared to the pre-treatment sample.
Statistical methods
All statistical analyses were conducted using the R environment (Ihaka and Gentleman, 1996) and the R packages "Statistics for Microarray Analysis" (Dudoit et al., 2002) . For cDNA microarray analysis all spots from each microarray were included in the analysis. Data normalization was performed using scaled loess normalization and differential genes were identified using an empirical Bayes method for analysing replicated microarray data (Lönnstedt and Speed, 2002) . Affymetrix microarrays were analyzed using the R packages affy and affy-PLM (Ihaka and Gentleman, 1996) . Background subtraction and normalization was performed as previously described (Li and Wong, 2001 ). Filtering of genes that either had more than 30% absent calls or that did not show significant variation in gene expression across arrays was performed as described (Simon, 2004) . Correlation of the expression of TGFBI with ECM-related genes was estimated using Pearson's correlation coefficients. 
